Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models
© Blurton-Jones et al.; licensee BioMed Central Ltd. 2014
Received: 4 November 2013
Accepted: 18 February 2014
Published: 16 April 2014
Short-term neural stem cell (NSC) transplantation improves cognition in Alzheimer’s disease (AD) transgenic mice by enhancing endogenous synaptic connectivity. However, this approach has no effect on the underlying beta-amyloid (Aβ) and neurofibrillary tangle pathology. Long term efficacy of cell based approaches may therefore require combinatorial approaches.
To begin to examine this question we genetically-modified NSCs to stably express and secrete the Aβ-degrading enzyme, neprilysin (sNEP). Next, we studied the effects of sNEP expression in vitro by quantifying Aβ-degrading activity, NSC multipotency markers, and Aβ-induced toxicity. To determine whether sNEP-expressing NSCs can also modulate AD-pathogenesis in vivo, control-modified and sNEP-NSCs were transplanted unilaterally into the hippocampus of two independent and well characterized transgenic models of AD: 3xTg-AD and Thy1-APP mice. After three months, stem cell engraftment, neprilysin expression, and AD pathology were examined.
Our findings reveal that stem cell-mediated delivery of NEP provides marked and significant reductions in Aβ pathology and increases synaptic density in both 3xTg-AD and Thy1-APP transgenic mice. Remarkably, Aβ plaque loads are reduced not only in the hippocampus and subiculum adjacent to engrafted NSCs, but also within the amygdala and medial septum, areas that receive afferent projections from the engrafted region.
Taken together, our data suggest that genetically-modified NSCs could provide a powerful combinatorial approach to not only enhance synaptic plasticity but to also target and modify underlying Alzheimer’s disease pathology.
Alzheimer’s disease (AD) is the leading cause of age-related dementia, afflicting one in every eight people over the age of 65 . Unfortunately, the incidence of dementia is expected to quadruple over the next 40 years, such that more than 115 million people will be afflicted world-wide by 2050 . Currently approved therapies offer only marginal, temporary relief and fail to modify the underlying disease pathology. Thus, there is a critical and urgent need to examine novel and combinatorial approaches to treat this devastating disorder.
Pathologically, AD is characterized by the accumulation of two hallmark brain lesions, beta-amyloid (Aβ) plaques and neurofibrillary tangles (NFTs). Aβ plaques result from the extracellular accumulation of insoluble aggregates of a small 40 to 42 amino acid peptide, Aβ. NFTs in contrast, consist of intraneuronal insoluble aggregates of the microtubule binding protein, tau, which becomes hyperphosphorylated and compromises neuronal activity, connectivity and function. In addition to the accumulation of Aβ and tau across multiple brain regions, AD patients also exhibit inflammation and widespread synaptic and neuronal loss.
Given the complex nature of this disease and the multiple pathways and regions affected, a single small molecule approach may not provide substantial benefit in the absence of other interventions. Biologic-based approaches, such as stem cell transplantation, are therefore receiving increasing attention. Recently, we and others showed that neural stem cell (NSC) transplantation markedly improves cognitive function, synaptic connectivity and neuronal survival in models of AD and tauopathy [3, 4]. Many of these effects appear to be mediated by stem cell-derived neurotrophins or other neuroprotective activities. Mesenchymal stem cells have also been found to improve cognition in AD models by modulating cytokine levels and brain inflammation . Thus, stem cells provide therapeutic efficacy in preclinical models of AD by modulating complex biological systems via multiple mechanisms. Although short-term benefits of stem cell transplantation appear promising and warrant further examination, these studies have also shown that NSCs do not modify the underlying Aβ or tau pathology [3, 4]. Hence, it is critical to examine combinatorial approaches aimed at not only improving synaptic connectivity and neuronal function but also diminishing Aβ and tau accumulation.
Over the last decade, pathways that underlie the endogenous degradation of Aβ have been identified. Among these, the proteolytic enzyme neprilysin (NEP) exhibits some of the most potent activity [6, 7]. Interestingly, levels and activity of NEP are decreased in AD brains, suggesting that a reduction in Aβ degradation may contribute to the development of the disease [8, 9]. Approaches that enhance or harness these degradation pathways may provide important disease-modifying efficacy. In support of this, transgenic or viral-mediated overexpression of NEP reduces Aβ pathology [7, 10]. Unfortunately, widespread delivery of these therapeutic proteins to the large human brain will likely be required, but is hindered by the blood brain barrier and the limited radius of infectivity (<0.5 mm) afforded by current viral-based approaches . One possible solution to this problem is to harness the migratory activity of NSCs  and use these cells to deliver Aβ-degrading enzymes throughout the forebrain.
In this study, we hypothesized that NSCs could provide an effective means to deliver disease-modifying therapeutic proteins to the brain. To test this hypothesis, we generated murine NSC lines that overexpress a secreted form of the Aβ-degrading enzyme, neprilysin (sNEP). In vitro characterization of these cells revealed high levels of sNEP protein expression and no changes to NSCs markers or differentiation potential. sNEP expression also protected NSCs against Aβ-induced toxicity both in vitro and in vivo. Most critically, these cells survive and continue to produce sNEP for several months following transplantation, markedly reducing Aβ pathology and enhancing synaptic connectivity in two independent transgenic models. Thus, sNEP-expressing NSCs represent a promising therapeutic approach that combines the neurotrophic-mediated benefits of stem cell transplantation with the widespread delivery of a disease-modifying protein.
All animal experiments were approved by the University of California, Irvine Institutional Animal Care & Use Committee and were performed in strict accordance with National Institutes of Health guidelines. The 3xTg-AD and Thy1-APP mice have previously been described [13–15]. 3xTg-AD mice were generated by co-microinjecting transgenes expressing human APP695 with the Swedish mutation (KM670/671NL) and human tau with the P301L mutation under control of the murine Thy1.2 promoter into single-cell embryos of homozygous PS1M146V knockin mice. Thy1-APP mice were generated by pronuclear injection of a transgene expressing APP751 with Swedish and London (V717I) mutations under control of the murine Thy1 promoter. The 3xTg-AD mice are maintained on a hybrid C57BL6/129 background and Thy1-APP mice are maintained as purebred C57/Bl6. Equivalent numbers of both male and female mice were utilized in this study and housed on a 12-hour light/dark schedule with ad libitum access to food and water. Importantly, both C57Bl6 and 129 background strains have the identical major histocompatibility complex (MHC) haplotype (H-2b) as the C57Bl6-derived NSCs utilized in this study.
Neural stem cells
The neural stem cells used for transplantation into 3xTg-AD mice were isolated from postnatal day 1 GFP-expressing transgenic mice as previously described . NSCs transplanted into Thy1-APP mice were derived from the C57Bl6 E15 cortex (Millipore SCR029). NSC lines were grown as adherent monolayers using standard NSC media ((D)MEM/F12 with Glutamax, N2, epidermal growth factor (EGF)). To generate lines that stably expressed s-NEP or empty vector control (pBOBI), GFP-NSC cultures were transfected with 5 μg of plasmid using an AMAXA nucleofector (program A-33) following standard protocols (Lonza Inc. Alpharetta, GA, USA). Cells were maintained using standard media and three days after nucleofection, selective antibiotic (Zeocin 100 ng/ml, Invivogen, San Diego, California, USA) was added. Media were changed every two days and cells were split as needed. After six weeks of stable selection, cells were frozen down or utilized for experiments. For Thy1-APP studies, NSCs were transduced with lentiviral particles (multiplicity of infection (MOI) = 50) generated by transfection of HEK293 cells with s-NEP or p-BOBI lentiviral and packaging plasmids as described . For transplantation, control and s-NEP-expressing NSCs were lightly trypsinized, washed three times, triturated and filtered through a 70 μm mesh. Cells were then counted and resuspended in vehicle (1× Hanks balanced salt solution with 20 ng/ml hEGF) at a density of 50,000 cells/μl.
Control- and sNEP-transfected NSCs were delivered to the hippocampus or subiculum using a stereotaxic apparatus. For 3xTg-AD mice, NSCs were injected into the subiculum using the following coordinates relative to Bregma: AP: -3.6, ML: ±2.1, DV: -2.0. Thy1-APP mice received intrahippocampal injections using coordinates: AP: -2.0, ML: ±1.5, DV: -1.3. The 3xTg-AD mice were anesthetized with isofluorane, placed in the stereotax and injected with 100,000 control-transfected NSCs into one subiculum/hippocampus (2 μl/injection) and 100,000 sNEP-NSCs into the other hippocampus using a 5 μl Hamilton microsyringe (30-gauge) and an injection rate of 0.5 μl/minute. The side receiving sNEP cells was randomly chosen and recorded for each animal. Thy1-APP mice underwent similar surgeries except that one side of the hippocampus received a vehicle injection whereas the other side received either sNEP- or control-NSCs. Accurate placement of the injection to the targeted region was confirmed for all animals by visualization of the needle tract within coronal brain sections.
The 3xTg-AD mice were sacrificed three months after transplantation and the Thy1-APP mice were sacrificed one month after transplantation via Nembutal overdose and cardiac perfusion with 0.01 M phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (pH 7.4). Brains were rapidly removed and post-fixed for an additional 24 hours at 4°C. Prior to sectioning, a notch was made in the bottom left cortex so that left versus right sides could be readily distinguished after sectioning. Brains were then cut in 50 μm thick coronal sections on a Vibratome and stored in PBS with 0.02% NaN3 at 4°C until use.
Fluorescent labelling followed standard protocols as previously described [3, 17]. Primary antibodies utilized include: antibodies against Aβ: 6E10 (Signet, Dedham, MA, USA), fibrillar Aβ (OC, gift of C. Glabe), Tau: HT7 (Innogenetics, Alpharetta, GA, USA), phospho-Tau (Ser 199/202, AT8 epitope; Invitrogen, Carlsbad, CA, USA), glial fibrillary acidic protein (GFAP) (Dako, Carpinteria, CA, USA), β-III-tubulin, GFP, GalC, active caspase-3 and CNPase (Millipore, Carlsbad, CA, USA), Doublecortin (Santa Cruz Biotech, Santa Cruz, CA, USA), and synaptophysin (Sigma, St. Louis, MO, USA). Primary antibodies were applied overnight at 4°C and detected with appropriate Alexa Fluor conjugated secondary antibodies (Invitrogen). Specificity of all primary antibodies was confirmed by Western blot and by omission of primary antibody in immunofluorescent labelling (data not shown).
SDS-PAGE western blots and Aβ sandwich ELISAs were performed following standard protocols as previously described . Primary antibodies used for western blot analysis include: nestin, sox-2, musashi-1 (Millipore), NEP/CD10 (Vector Biolabs, Burlingame, CA, USA), and brain-derived neurotrophic factor (BDNF, Santa Cruz Biotechnology). To test the effects of Aβ treatment on NSC viability cells were treated with 10 nM Aβ42 for 24 hours and then lactate dehydrogenase (LDH) release into the media was measured using the CytoTox 96 LDH assay (Promega Corporation, Madison, WI, USA) following the manufacturer’s protocol.
Confocal microscopy and quantification
Immunofluorescent sections were visualized using a Leica TCS SPE or Biorad 1024 Confocal microscope. To avoid non-specific bleed-through, each laser line was excited and detected independently. All images represent either single confocal Z-slices or Z-stacks. For quantitative analysis, slides were coded and then images captured by a blinded observer using identical laser and detection settings. Grayscale Z-stack images were then analyzed using Image J software. Three square regions of interest (ROIs) were randomly defined within the area to be quantified (for example, subiculum) and then mean pixel intensity was computed by the software for each ROI. The three fields were averaged for each sample and means were compared by paired t-test.
Comparisons between multiple groups were performed using analysis of variance (ANOVA) followed by Fischer’s PLSD post hoc tests. Groups were considered significantly different when P <0.05 for both the ANOVA and post hoc comparisons. Aβ measurements were quantified from opposing sides of the brain from the same individual animals; the data were therefore compared by paired t-test. All statistical analysis was performed using Graphpad Prism software.
sNEP-expressing neural stem cells remain multipotent, degrade Aβ in vitro, and are resistant to Aβ toxicity
To determine whether sNEP-expressing NSCs can efficiently degrade Aβ, cultures of control- and sNEP-expressing NSCs were treated with recombinant human Aβ42 peptide and, 48 hours later, Aβ levels remaining within the media were measured by ELISA. Both the stably-transfected and lentiviral-transduced NSC lines efficiently degraded Aβ in vitro, reducing Aβ levels by more than 50% (Figure 1D, P = 0.0008 and Figure 2C, P = 0.03). Interestingly, we found that treatment of NSCs with 10 nM Aβ42 can trigger caspase-mediated cell death of NSCs within 24 hours (Figure 2). However, sNEP-expression significantly protects NSCs as evidenced by decreased LDH release and reduced caspase-3 activation versus Aβ-treated control NSCs (P = 0.03).
Transplanted sNEP-NSCs secrete neprilysin and degrade Aβ in vivo
Having verified that sNEP expression can promote Aβ degradation in vitro, we next performed stereotactic surgery to deliver sNEP-NSCs and control-NSCs into the brains of transgenic AD mice. NSCs were targeted to the subiculum or hippocampus of AD transgenic mice as both these regions develop robust Aβ plaque pathology, exhibit significant synaptic degeneration and are critical for learning and memory. Importantly, the hippocampus and subiculum are also dramatically affected in AD patients. Two complementary paradigms were pursued to deliver NSCs. In one set of experiments, 18-month-old 3xTg-AD transgenic mice were transplanted unilaterally with 100,000 sNEP-expressing NSCs into the subiculum and 100,000 control-transfected NSCs into the contralateral subiculum. Three months later, the 3xTg-AD mice were sacrificed and the brains examined. In the second paradigm, 9- month-old Thy1-APP transgenic mice were transplanted with 100,000 sNEP or control-transduced NSCs unilaterally into the hippocampus. The contralateral hippocampus received an equivalent injection of vehicle. One month after transplantation Thy1-APP mice were sacrificed and the brains examined.
Established tangle pathology is unchanged but synaptic density is increased by sNEP-NSCs
To determine the differentiated phenotype of engrafted cells, double-labeling for GFP and neuronal and glial markers was performed. We previously showed that murine NSCs transplanted into aged brains primarily express astrocytic markers [3, 20]. In this study we found similar results, detecting very few NSCs that co-expressed the neuronal marker NeuN (Figure 5F), but large numbers of GFP-expressing cells that co-expressed the astrocyte marker GFAP in both sNEP and control-NSC engrafted sides (Figure 5G-L). Similar gliogenic differentiation profiles were observed in both 3xTg-AD (Figure 5) and Thy1-APP mouse models (data not shown).
Neprilysin-expressing NSCs reduce plaques and increase synaptic density in a second transgenic model of AD
Neprilysin expression may enhance microglial Aβ phagocytosis
NSC transplantation may provide a promising new approach to treat AD by elevating neurotrophin levels and enhancing endogenous synaptic connectivity . However, NSCs do not modify Aβ pathology; thus, the long-term benefit of NSC transplantation remains unclear. Because of their robust migratory capacity, NSCs provide a compelling approach to deliver therapeutic proteins to the brain. By combining the inherent benefits of NSC transplantation with ex vivo gene therapy, modified NSCs may provide a powerful combinatorial approach to treat AD. In this study, we examined whether NEP-expressing NSCs could target and reduce Aβ pathology in two well-established transgenic models of AD. We found that NSCs could be readily modified to express and secrete NEP without altering multipotentcy or differentiation potential. More importantly, sNEP-expressing NSCs dramatically reduced Aβ levels both in vitro and in vivo and elevated synaptic density in both transgenic models of AD.
We and others previously tested the effect of NEP overexpression in transgenic AD mice [7, 10, 21, 22]. Each of these studies observed significant reductions in Aβ plaque load in response to NEP. We also previously demonstrated improved cognitive function in AD mice following lentiviral delivery of sNEP . In contrast, Meilandt and colleagues found no improvement in cognition when hAPP-J20 mice were crossed to mice overexpressing membrane-bound NEP . Major differences in delivery approach and the use of secreted versus membrane-bound forms of NEP likely account for these differences. In the current study, we again utilized the secreted form of neprilysinNEP, but instead used NSCs as a delivery vehicle. Potential benefits of NSC-mediated delivery over viral methods include a greater distribution of NEP delivery. Whereas NSCs have previously been shown to migrate through the brain parenchema , viral-based approaches typically provide only a small radius (approximately 0.5 mm) of infectivity . As the human brain is approximately three thousand times larger than the mouse brain, scale-up of viral gene-therapy for clinical translation remains a considerable challenge. Peripheral delivery of NEP protein also appears to be ineffective, as a recent study found that intravenous delivery of a NEP fusion protein could reduce plasma Aβ, but failed to clear Aβ plaques within the brain . New approaches, such as stem cell mediated delivery, may therefore be needed to provide broader expression of therapeutic proteins in the brain. However, it remains to be determined whether the migratory capacity of NSCs would be sufficient to treat a widespread brain disease such as AD. Clearly NSC-based delivery provides a benefit over current gene therapy approaches, but multiple NSC injections would likely still be needed.
The unilateral transplantation design used in this study allowed us to directly compare plaque load and synaptic density within the same animals. Unfortunately, this design also precluded further biochemical analysis of soluble Aβ. It, therefore, remains possible that soluble Aβ levels are not altered by this approach. However, the observed sNEP-NSC mediated a 31.8% increase in synaptic density, suggesting that soluble Aβ oligomers are also likely reduced. Previous studies also support this notion, as lentiviral-mediated delivery of s-NEP reduces both soluble and insoluble Aβ . As most transgenic AD models, including those used, exhibit little or no neuronal loss we conclude that the effect of sNEP-NSCs on synaptic density is mediated via maintenance and/or enhancement of endogenous synaptic connectivity. It is important to note that synapse loss correlates strongly with cognitive dysfunction in AD patients . Quite notably in the current study we observed a 31.8% increase in hippocampal synaptic density three months after sNEP-NSC transplantation. The magnitude of this effect is similar to the approximately 38% loss of synapses that occurs in AD patients . We, therefore, conclude that the effect of sNEP-NSCs on synaptic density represents a meaningful functional outcome. In addition to Aβ plaques and synaptic loss, cerebral amyloid angiopathy (CAA) represents another important AD-associated pathology. However, neither the 3xTg-AD nor Thy1-APP models develop CAA at the ages studied. Future experiments are therefore needed to determine whether NSC-mediated NEP delivery can also influence CAA.
Other cell types may also be useful for delivering NEP to the AD brain. For example, induced pluripotent stem cells (iPSCs) offer an alternative and extremely promising new cell source that could be used to deliver NEP and personalized cell therapies. Two distinct advantages of iPSC-derived NSCs over allogeneic fetal-derived NSCs include the greatly increased capacity for scale-up and the potential ability to transplant a patient’s own cells, thereby reducing or eliminating the need for immune-suppression. Most recently, xeno-free clinical grade iPSCs have been generated, moving this approach several important steps closer to clinical reality .
Peripheral-derived cells are also worth considering. In support of this, Lebson and colleagues transfected CD11b + monocytes with NEP and infused these cells biweekly into AD transgenic mice . Some of these modified monocytes migrated into the brain and Aβ deposition was slowed. This promising approach further supports the notion that cell-based delivery of NEP can be used to target Aβ. However, the use of monocytes offers both advantages and disadvantages in comparison to NSC-based delivery. Monocytes, for example, have limited half-lives; thus, repeated injections are required. This potential drawback can also be viewed as a possible advantage by providing some protection against adverse events. Interestingly, upregulation of NEP, also known as CALLA (common acute lymphoblastic leukemia antigen), commonly occurs in acute leukemias . The overexpression of NEP in hematopoetic lineages is therefore concerning. It is also worth noting that without irradiation, concurrent stroke, or additional treatments, very few monocytes appear to migrate into the AD brain . Thus, monocyte mediated delivery of NEP may not provide as robust a therapeutic approach as NSC-based delivery.
In contrast, our data suggest that the disease-modifying effects of sNEP-NSCs can be extremely robust, modulating Aβ plaques in regions both adjacent to and interconnected with the grafted area. Reductions in local Aβ appear to occur via both NEP-mediated proteolysis and enhanced microglial degradation. The mechanism(s) by which sNEP-NSCs decrease plaque load in more distant regions, such as the amygdala and medial septum, however, remains unclear. Transplanted NSCs did not migrate into the amygdala or medial septum and we were unable to detect clear evidence of axonally-transported NEP. sNEP-NSCs may instead modulate the production and/or anterograde transport of Aβ from the hippocampus to these efferent targets. Intriguingly, recent studies point toward a network diffusion model for the transmission of neurodegenerative pathologies via synaptic networks [29, 30]. In light of this, our results could indicate that therapeutic proteins might also effectively modulate pathology via the same neural networks.
In conclusion, the current study clearly demonstrates that sNEP-expressing NSCs offer a novel and highly effective combinatorial approach to modify AD pathology and enhance synaptic connectivity. Future studies will be needed to determine whether this combinatorial approach can also provide additional long-term behavioral efficacy and whether such approaches can be translated towards an eventual clinical application.
triple transgenic mouse model of Alzheimer’s Disease
analysis of variance
brain-derived neurotrophic factor
common acute lymphoblastic leukemia antigen
(Dulbecco's) modified Eagle’s medium
epidermal growth factor
enzyme-linked immunosorbent assay
glial fibrillary acid protein
green fluorescent protein
major histocompatibility complex
neural stem cell
protected least significant difference
region of interest
sex determining region Y-box 2
thymus cell antigen 1.
This work was supported by CIRM TR1-01245 and the American Health Assistance Foundation (FML), AG029378, AG16573 and Alzheimer’s Association NIRG 12-242-550 (MBJ), AG022074, AG18440, AG10435 (EM), the Else-Kröner Fresenius Stiftung (FJM), and CIRM RT1-01108 and Alzheimer’s Association IIRG-05-14975 (JFL).
- Thies W, Bleiler L: Alzheimer’s disease facts and figures. Alzheimers Dement. 2011, 2011: 208-244.Google Scholar
- Prince MJ, Ferri CP, Sousa R, Albanese E, Ribeiro WS, Honyashiki M: World Alzheimer Report 2009: The Global Prevalence of Dementia. 2009, London: Alzheimer Disease International, Available at: http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf,Google Scholar
- Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF, Yamasaki TR, Poon WW, Green KN, LaFerla FM: Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A. 2009, 106: 13594-13599. 10.1073/pnas.0901402106.PubMed CentralView ArticlePubMedGoogle Scholar
- Hampton DW, Webber DJ, Bilican B, Goedert M, Spillantini MG, Chandran S: Cell-mediated neuroprotection in a mouse model of human tauopathy. J Neurosci. 2010, 30: 9973-9983. 10.1523/JNEUROSCI.0834-10.2010.View ArticlePubMedGoogle Scholar
- Lee HJ, Lee JK, Lee H, Carter JE, Chang JW, Oh W, Yang YS, Suh JG, Lee BH, Jin HK, Bae JS: Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer’s disease mouse model through modulation of neuroinflammation. Neurobiol Aging. 2010, 33: 588-602.View ArticlePubMedGoogle Scholar
- Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC: Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000, 6: 143-150. 10.1038/72237.View ArticlePubMedGoogle Scholar
- Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ: Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003, 40: 1087-1093. 10.1016/S0896-6273(03)00787-6.View ArticlePubMedGoogle Scholar
- Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM: Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging. 2005, 26: 645-654. 10.1016/j.neurobiolaging.2004.06.013.View ArticlePubMedGoogle Scholar
- Wang S, Wang R, Chen L, Bennett DA, Dickson DW, Wang DS: Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer’s brain. J Neurochem. 2010, 115: 47-57. 10.1111/j.1471-4159.2010.06899.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, Verma IM, Masliah E: Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci. 2003, 23: 1992-1996.PubMedGoogle Scholar
- de Backer MW, Brans MA, Luijendijk MC, Garner KM, Adan RA: Optimization of adeno-associated viral vector-mediated gene delivery to the hypothalamus. Hum Gene Ther. 2010, 21: 673-682. 10.1089/hum.2009.169.View ArticlePubMedGoogle Scholar
- Muller FJ, Snyder EY, Loring JF: Gene therapy: can neural stem cells deliver?. Nat Rev Neurosci. 2006, 7: 75-84. 10.1038/nrn1829.View ArticlePubMedGoogle Scholar
- Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM: Intraneuronal Abeta causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron. 2005, 45: 675-688. 10.1016/j.neuron.2005.01.040.View ArticlePubMedGoogle Scholar
- Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM: Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003, 39: 409-421. 10.1016/S0896-6273(03)00434-3.View ArticlePubMedGoogle Scholar
- Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E: Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1–42). J Neurosci Res. 2001, 66: 573-582. 10.1002/jnr.1247.View ArticlePubMedGoogle Scholar
- Mizumoto H, Mizumoto K, Shatos MA, Klassen H, Young MJ: Retinal transplantation of neural progenitor cells derived from the brain of GFP transgenic mice. Vision Res. 2003, 43: 1699-1708. 10.1016/S0042-6989(03)00235-9.View ArticlePubMedGoogle Scholar
- Blurton-Jones M, Laferla FM: Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res. 2006, 3: 437-448. 10.2174/156720506779025242.View ArticlePubMedGoogle Scholar
- Pitkanen A, Pikkarainen M, Nurminen N, Ylinen A: Reciprocal connections between the amygdala and the hippocampal formation, perirhinal cortex, and postrhinal cortex in rat. A review. Ann N Y Acad Sci. 2000, 911: 369-391.View ArticlePubMedGoogle Scholar
- Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM: Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004, 43: 321-332. 10.1016/j.neuron.2004.07.003.View ArticlePubMedGoogle Scholar
- Yamasaki TR, Blurton-Jones M, Morrissette DA, Kitazawa M, Oddo S, LaFerla FM: Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci. 2007, 27: 11925-11933. 10.1523/JNEUROSCI.1627-07.2007.View ArticlePubMedGoogle Scholar
- Spencer B, Marr RA, Rockenstein E, Crews L, Adame A, Potkar R, Patrick C, Gage FH, Verma IM, Masliah E: Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice. BMC Neurosci. 2008, 9: 109-10.1186/1471-2202-9-109.PubMed CentralView ArticlePubMedGoogle Scholar
- Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, Scearce-Levie K, Cheng IH, Yu GQ, Mucke L: Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci. 2009, 29: 1977-1986. 10.1523/JNEUROSCI.2984-08.2009.PubMed CentralView ArticlePubMedGoogle Scholar
- Walker JR, Pacoma R, Watson J, Ou W, Alves J, Mason DE, Peters EC, Urbina HD, Welzel G, Althage A, Liu B, Tuntland T, Jacobson LH, Harris JL, Schumacher AM: Enhanced proteolytic clearance of plasma abeta by peripherally administered neprilysin does not result in reduced levels of brain abeta in mice. J Neurosci. 2013, 33: 2457-2464. 10.1523/JNEUROSCI.3407-12.2013.View ArticlePubMedGoogle Scholar
- Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R: Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991, 30: 572-580. 10.1002/ana.410300410.View ArticlePubMedGoogle Scholar
- Awe JP, Lee PC, Ramathal C, Vega-Crespo A, Durruthy-Durruthy J, Cooper A, Karumbayaram S, Lowry WE, Clark AT, Zack JA, Sebastiano V, Kohn DB, Pyle AD, Martin MG, Lipshutz GS, Phelps PE, Pera RA, Byrne JA: Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status. Stem Cell Res Ther. 2013, 4: 87-10.1186/scrt246.PubMed CentralView ArticlePubMedGoogle Scholar
- Lebson L, Nash K, Kamath S, Herber D, Carty N, Lee DC, Li Q, Szekeres K, Jinwal U, Koren J, Dickey CA, Gottschall PE, Morgan D, Gordon MN: Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J Neurosci. 2010, 30: 9651-9658. 10.1523/JNEUROSCI.0329-10.2010.PubMed CentralView ArticlePubMedGoogle Scholar
- Bene MC, Faure GC: CD10 in acute leukemias. GEIL (Groupe d’Etude Immunologique des Leucemies). Haematologica. 1997, 82: 205-210.PubMedGoogle Scholar
- Rezai-Zadeh K, Gate D, Gowing G, Town T: How to get from here to there: macrophage recruitment in Alzheimer’s disease. Curr Alzheimer Res. 2011, 8: 156-163. 10.2174/156720511795256017.PubMed CentralView ArticlePubMedGoogle Scholar
- Palop JJ, Mucke L: Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci. 2010, 13: 812-818. 10.1038/nn.2583.PubMed CentralView ArticlePubMedGoogle Scholar
- Raj A, Kuceyeski A, Weiner M: A network diffusion model of disease progression in dementia. Neuron. 2012, 73: 1204-1215. 10.1016/j.neuron.2011.12.040.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.